Loading patent…
AssigneeCentro Nacional de Investigaciones Oncologicas (CNIO)
InventorsManuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina
Estimating the term…
The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
A method of treating or preventing a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgc1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes, comprising administering to a subject in need thereof a phosphoinositide 3-kinase inhibitor.
Dependencies are inferred from the claim text.